As you will be aware, NICE will be undertaking a CDF review of TA620 Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. I am writing to inform you that following on from discussions with the company, the timelines for this review have now been revised.
This review will be conducted using the shorter process that was in use prior to the publication of the updated manual for NICE health technology evaluations in February this year. For details of this process see https://www.nice.org.uk/process/pmg19/chapter/reviews#updating-technology-appraisal-guidance-for-technologies-included-in-the-cancer-drugs-fund. This means that the review will only cover the population for which olaparib was recommended for use in the CDF in TA620, and the scope will revert to that used for TA620. The updated draft scope that was consulted on earlier this year can be disregarded.
It is now expected that the invitation to participate will be released during late-May 2022. The deadline for submissions is expected in approximately late-June 2022.